Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-685-3 | CAS number: 68604-33-1 This substance is identified by SDA Substance Name: C14-C18 and C16-C18 unsaturated alkyl carboxylic acid ammonium salt and SDA Reporting Number: 04-006-01.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
oral: Based on read across studies for acute oral toxicity on chemically similar substances, the LD50(oral) for Fatty acids, C14-18 and C16-18-unsatd., ammonium salts is estimated to be >5000 mg/kg.
dermal: Based on read across studies for acute dermal toxicity on chemically similar substances and the weight of evidence approach, the LD50(dermal) for Fatty acids, C14-18 and C16-18-unsatd., ammonium salts is estimated to be >5000 mg/kg.
inhalation - vapours: Based on the low acute oral toxicity (LD50(oral): >5000mg/kg) and the tiny vapour pressure (Vapour pressure(25°C): <0.01 Pa) of Fatty acids, C14-18 and C16-18-unsatd., ammonium salts, no acute inhalation toxicity of a at 25°C saturated atmosphere of vapours of this substances is expected.
inhalation - dust/mist: data lacking; (Based on the intended use of the products containing Fatty acids, C14-18 and C16-18-unsatd., ammonium salts, exposition to dust/mist of this substance are not expected.).
intravenous: After intravenous application, a LD50 of approximately 267 mg/kg bw was determined for a analogue substance.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- Read-across (analogue): For justification of read-across see section 13.2.
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 42 097 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: Value of oleic acid.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Based on GHS criteria the target substance "Fatty acids, C14-18 and C16-18-unsatd., ammonium salts" is not considered to be classified for acute oral toxicity.
Based upon the DSD classification criteria (67/548/EEC) the target substance is not considered to be classified for Harmful, Toxic or Very toxic if swallowed. - Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- not given
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- yes
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS:
2 groups with 5 male and female rats each.
- Source: raiser: Winkelmann, Hannover.
- Weight at study initiation: 168g (male rats), 143g (female rats).
- Fasting period before study: 18 hours
- Housing: 5 animals per cage, separated by sexes.
- Diet: laboratory standard diet (altromin) and water water ad libitum.
The test animals were provided food (ad libitum) 3 hours after application.
ENVIRONMENTAL CONDITIONS
- Temperature: 22°C;
- Humidity (%): 45-60%;
- Air changes (per hr): not given;
- Photoperiod (hrs dark / hrs light): 12 hours. - Route of administration:
- oral: gavage
- Vehicle:
- other: 25% aqueous suspension
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 25%;
- Amount of vehicle (if gavage): 20ml/kg.
MAXIMUM DOSE VOLUME APPLIED: 5g/kg.
DOSAGE PREPARATION (if unusual): for preparation of the suspention were used lukewarm aqua dest.. The supension was kept in movement with magnetic stirrer for applying an even mixed suspension to the test animals.
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: Based on chemical composition a less acute toxicity of the test item was expected. Because of that a limit test with a dosis of 5g/kg body weight was proved. - Doses:
- 5 g/kg bw
- No. of animals per sex per dose:
- 10 animals per dose including both male and female animals
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days;
- Frequency of observations and weighing: daily observations;
- Necropsy of survivors performed: yes;
Other examinations performed: clinical signs, body weight. - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- All 10 rats survived the 14 days of observation.
- Clinical signs:
- No symptoms of poisoning were found during the observation.
- Body weight:
- see table below.
- Gross pathology:
- No symptoms of poisoning or inflammations neither on the inner organs nor the visceral cavities were found.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The test item proves to be low acute toxicity. The LD50 can be declared for male and female rats: >5 g/kg.
- Executive summary:
The carboxylic acid Edenor Ti (Edenor Talg A) was tested for acute oral toxicity according to OECD guidline 401 by limit test. It was proved to be less acute toxic at peroral application on rats (LD50 >5 g/kg bw).
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1970-05-21- to 1970-06-01
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: non-GLP study, similar to OECD Guideline.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Species:
- rat
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Fasting period before study: 24 hours
- Weight at study initiation: 200-300 g
- Housing: 5 animals per cage - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Doses:
- 4, 8, 16, 32, 48, 64 mL/kg, these values correlate to the following: 5262.125, 10524.25, 21048.5, 42097, 63145.5, 84194 mg/kg bw
- No. of animals per sex per dose:
- 5 animals per dose including both male and female animals
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: daily observations
- Necropsy of survivors performed: no
- Other examinations performed: clinical signs - Sex:
- male/female
- Dose descriptor:
- LD0
- Effect level:
- 32 mL/kg bw
- Based on:
- test mat.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 47.3 mL/kg bw
- Based on:
- test mat.
- 95% CL:
- > 40.9 - < 54.7
- Remarks on result:
- other: 47.3 mL/ kg bw can be converted to 42097 mg/kg bw using the densitiy of the substance (0.89 g/cm^3 = densitiy of CAS 112- 80-1)
- Sex:
- male/female
- Dose descriptor:
- LD100
- Effect level:
- 64 mL/kg bw
- Based on:
- test mat.
- Mortality:
- Mortality occured from the 40 mL/kg bw dose group onwards. 1 animal of that dose group died on day 2, 3 animals of the 48 mL/kg bw dose group and all animals of the 64 mL/kg bw dose group died on day 1.
- Clinical signs:
- All dosage levels from 16 mL/kg and above had nasal hemorrhage, crustated occular areas, oozed urine and appeared to be debilitated prior to death.
- Body weight:
- no data
- Gross pathology:
- no data
Referenceopen allclose all
Body weight average in g of each 5 test animals before and after application:
dose |
sex |
before application |
24 h after application |
7 d after application |
14 d after application |
5 g/kg |
male | 168.0 | 180.0 | 202.0 | 218.0 |
5 g/kg | female | 143.0 | 152.0 | 159.0 | 164.0 |
As its seen in the table the application of 5 g/kg had no impact on the body weight progress of the test animals.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
- Quality of whole database:
- GLP study according to OECD Guideline and non-GLP study, equivalent or similar to OECD Guideline. Please refer to IUCLID section 13.2 for read across justification.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Justification for type of information:
- Read-across justification / weight of evidence justification:
The target substance Fatty acids, C14-18 and C16-18-unsatd., ammonium salts consists of ammonium salts of the fatty acids Myristic Acid (C14 ), Palmitic acid (C16), Stearic acid (C18), Palmitoleic acid (C16:1), Oleic acid (C18:1), Linoleic acid (C18:2) and Linolenic acid (C18:3). Information on acute dermal toxicity of Ammonium stearate (LD50(dermal): >3000mg/kg), Oleic Acid (LD50(dermal): >3000mg/kg), Stearic acid (LD50(dermal): >5000mg/kg), Linolenic acid (LD50(dermal): >18000mg/kg) and Ammonium sulfate (LD50(dermal): >2000mg/kg) is available. These substances are either the soap Ammonium stearate contained in the target substance, several fatty acids from which the target substance is manufactured or the Ammonium sulfate. Additionally the estimated acute oral toxicity of the target substance is low (LD50(oral): >5000 mg/kg). The effects of acute oral toxicity and acute dermal toxicity are expected to be equal or similiar, based on the low water solubility (< 1 mg/L), the Partition coefficient (log Pow: 3,1 - 5,1) and the molecular weight (245-302g/mol; average 297g/mol).
Based on these available data on acute dermal toxicity and the acute oral toxicity of the target substance, the LD50(dermal) is estimated to >5000mg/kg. - Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Based on GHS criteria the target substance "Fatty acids, C14-18 and C16-18-unsatd., ammonium salts" is not considered to be classified for acute dermal toxicity.
Based upon the DSD classification criteria (67/548/EEC) the target substance is not considered to be classified for Harmful, Toxic or Very toxic in contact with skin.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
- Quality of whole database:
- Estimation based on read across studies on chemically similar substances and weight of evidence approach.
Additional information
No adequate animal data are available and no epidemiological studies investigating the acute toxicity of the test (target) substance were identified. However, data from a structural analogue (read across substance) are available.
Oral:
Several publication are available in which the acute oral toxicity on rats of the analogue substances (Fatty acids, C16-18 and C18-unsatd., Oleic acid) were determined. As results, the following LD50(oral) values were determined: >5000 mg/kg bw for Fatty acids, C16-18 and C18-unsatd. and 47.3 mL/kg bw (which correlates to 42097 mg/kg bw) for Oleic acid. Based on the structural similarity of the target substance to the analogue substances the results of the acute oral toxicity of the source substances can be assigned to the target substance.
The supporting information of the acute oral toxicity of the analogue substances are also available: Ammonium stearate (LD50(oral, rat): > 5 000 mg/kg bw), Sodium stearate (LD50(oral, rat): > 5 000 mg/kg bw), Oleic Acid (LD50(oral, rat): > 5 000 mg/kg bw and LD50(oral, rat): 57g/kg bw), Myristic Acid (LD50(oral, rat): > 10 000 mg/kg bw), Palmitic Acid (LD50(oral, rat): > 10 000 mg/kg bw), Stearic acid (LD50(oral, rat): > 10 000 mg/kg bw and LD50(oral, rat): >5 000 mg/kg bw), Linoleic acid (LD50(oral, rat/mouse): >3 200 mg/kg bw), Linolenic acid (LD50(oral, rat/mouse): >3 200 mg/kg bw) and Ammonium sulfate (LD50(oral, rat/mouse): > 2 000 mg/kg bw). This support information circumstantiates the result of the read-across projection to acute oral toxicity of the target substance.
Dermal:
Several publication are available in which the acute dermal toxicity on rats of the analogue substances (Ammonium stearate, Oleic acid, Stearic acid, Linoleic acid, Linolenic acid and Ammonium sulfate) were determined. As results, the following LD50(dermal) values were determined: > 3 000 mg/kg bw for Ammonium stearate, > 3 000 mg/kg bw for Oleic Acid, >5 000 mg/kg bw for Stearic acid, >18 g/kg bw for Linoleic acid, >18 g/kg bw for Linolenic acid and > 2 000 mg/kg bw for Ammonium sulfate.
Based on the structural similarity of the target substance to the analogue substances, the read across studies for acute dermal toxicity on chemically similar substances and the weight of evidence approach, the LD50(dermal) for Fatty acids, C14-18 and C16-18-unsatd., ammonium salts is estimated to be >5000 mg/kg.
Intravenous:
In a publication an experiment is described in which 9-octadecenoic acid was administered to rats by intravenous injections to investigate the effects on the lungs. Therefore, adult male Fischer 344 rats were used. As injections of about 80 µL (356 mg/kg bw) of the analogue substance led to a high rate of mortality (compared to similar doses administered to larger animals in other studies) and because injecting of smaller amounts was not feasible, the doses were reduced by suspending the read across substance in saline-albumin solution in a ratio of 1:5. A volume of 250 µL of this suspension then was injected via the penile vein in anesthetized rats. They were sacrificed after different time intervals: 10 minutes, 30 minutes, 1 hour, 6 hours, 24 hours, 4 days, 12 days and 4 weeks. Control animals received 1 mg/dL albumin solution. As a result, histologic changes in the lungs (perivascular interstitial and intra-alveolar edema, vascular congestion, intravascular coagulation, intra-alveolar hemorrhage) were found within minutes after application. After 24 hours, an interstitial infiltrate of alveolar lining cells and macrophages was observed. Further development of the lesion was comparable to the respiratory distress syndrome. Chronic pulmonary inflammation or fibrosis was not found. The LD50 of the read across substance as a suspension in albumin was approximately 60 µL. The LD50 value 60 µL (given in the publication) was converted using the substance densitiy (0.89 g/cm3): 60 µL*0.89 g/1 mL=0.06 mL*0.89 g/mL=0.0534 g, weight rats: max. 200 g; 53.4 mg/0.2 kg = 267 mg/kg.
In another publication the effects of intravenous injections of an analogue substance on the lungs of dogs are examined. The substance was administered at two dose levels in a single injection (0.045 g/kg bw or 0.09 g/kg bw). Control animals received normal saline injections. Animals of the single-injection-groups were sacrificed after 1, 2, 4, 6 and 24 hours and 1, 2 and 4 weeks after injection. Additionally, 3 dogs of the 0.09 g/kg group were sacrificed at 3, 12 and 48 hours. As a result, mostly ventral and subpleural hemorrhagic lesions were observed in the early stage. Later yellow-tan patches were seen over the pleura. Lesions occurred mostly on the ventral sides of the lower lobes. Light microscopic examination revealed normal lung areas and damaged areas, these were more distinct in the higher dose group of the single injection-group. Large microcysts were seen in the peripheral portions of the lobe. After 1 week acute lesions had disappeared except for moderate edema. Fibrotic areas scattered over the lungs were found as well as thickened alveolar walls containing macrophages. These macrophages were less numerous after 2 weeks and 1 month, but the extent of fibrosis increased.
Justification for classification or non-classification
Based on GHS criteria the target substance "Fatty acids, C14-18 and C16-18-unsatd., ammonium salts" is not considered to be classified for acute (oral/dermal) toxicity.
Based upon the DSD classification criteria (67/548/EEC) the target substance is not considered to be classified as Harmful, Toxic or Very toxic (if swallowed/in contact with skin).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.